KRAS and familial pancreatic carcinoma: Additionally we performed the same procedure in a pancreatic cancer cell line PANC1, which, as in the majority of PDACs, contains coexpressed KRAS and TP53 mutants, and hyperactive MYC (Fig. 1A).